الفهرس 
ACKNOWLEDGEMENTOnly 14 pages are availabe for public view
 |  | from | 124 |  |  |
| | | from | 124 | | |
Abstract
The solubility and permeability of drugs are important factors that mainly affect absorption and bioavailability in the human body. This study aimed to enhance the solubility and bioavailability by encapsulating famotidine, a model proton pump inhibitor anti-ulcer drug, into a nano-spanlastic formulation. To create a mucoadhesive buccal drug delivery system, the nano-spanlastic formulation was incorporated into a CMC polymer solution to obtain a gel, and by using the lyophilization technique, a wafer was formulated. This bypassed first-pass metabolism, improved drug absorption and bioavailability and achieved non-invasive buccal delivery. Utilizing the Box-Behnken experimental design, the ethanol injection method was used to prepare famotidine-loaded nano-spanlastics. Investigations were done to explain how formulation factors affected the properties of nano-spanlastics. The optimized formula obtained from Design Expert® software containing Span as a nonionic surfactant and Tween as an edge activator: Particle size (170.6 ± 4.57 nm), polydispersity index PDI (0.368 ± 0.04) entrapment efficiency (68.89 ± 0.47%), zeta potential (-30.8 ± 1.95 mV), drug loading (7.41 ± 0.05) and excellent stability after storage were all characteristics of the ideal nano-spanlastic formulation. The wafer displayed good characteristics (pH, swelling index, drug content, ex vivo mucoadhesive residence time, and in vitro release rate).